Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States.

By L. Rahib, Benjamin D. Smith, R. Aizenberg, A. Rosenzweig, Julie M Fleshman, L. Matrisian. Cancer Research, 2014

6,276 citations recorded by the source corpus.

Subfields: Oncology

View Paper: https://www.semanticscholar.org/paper/bbcb5ab11a846d7eda4a53f321cd08b6b92d2824

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

1. Hans Clevers
2. R. Morgan
3. R. Sutherland
4. Giulia Biffi
5. D. Tuveson
6. C. Der
7. E. Musgrove
8. D. Öhlund

Citations in the corpus

• Organoid Models of Human and Mouse Ductal Pancreatic Cancer (2014, background): “Mortality due to pancreatic cancer is projected to surpass that of breast and colorectal cancer by 2030 in the United States (Rahib et al., 2014; Siegel et al., 2013).”
• Thyroid cancer mortality and incidence: A global overview (2015, background): “In most countries, incidence rates have been appreciably increasing over the last few decades,2,3 and if recent trends are maintained, thyroid cancer may become the fourth most common cancer by 2030 in the United States.4 Such an increase is likely due to improved ascertainment, diagnosis and certif”
• CANCER-ASSOCIATED FIBROBLAST EXOSOMES REGULATE SURVIVAL AND PROLIFERATION OF PANCREATIC CANCER CELLS (2016, neutral): “PDAC is currently the fourth leading cause of cancer-related deaths in the United States and is predicted to become the second leading cause of cancer-related deaths by 2030 (2).”
• KRAS: The Critical Driver and Therapeutic Target for Pancreatic Cancer (2018, background): “With a continued increase in incidence, pancreatic cancer is projected to become the second leading cause of cancer death by around 2020 (Rahib et al. 2014).”
• Vitamin D Receptor-Mediated Stromal Reprogramming Suppresses Pancreatitis and Enhances Pancreatic Cancer Therapy (2014, neutral): “Despite numerous attempts, the 5 year survival rate (6%) for pancreatic cancer has not changed in decades (Rahib et al., 2014).”
• Integrated Genomic Characterization of Pancreatic Ductal Adenocarcinoma (2017, neutral): “PDAC is predicted to become the second leading cause of cancer mortality by the year 2030 (Rahib et al., 2014).”
• Genomic analyses identify molecular subtypes of pancreatic cancer (2016, background): “Expression analysis defined 4 subtypes: (1) squamous; (2) pancreatic progenitor; (3) immunogenic; and (4) aberrantly differentiated endocrine exocrine (ADEX) that correlate with histopathological characteristics.”
• 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: What is new and what has changed? (2017, neutral): “By the year 2030, it is estimated that it will be the second leading cancer diagnosis in women and the ninth leading cancer diagnosis in men.(2) As a part of the revision process, we evaluated different recommendations and evidence grading systems, and we adopted a revised version of the grading sys”